ArticleMolecular cancer therapeutics2026

Identification and Nonclinical Characterization of SAR444200, a Novel Anti-GPC3 NANOBODY T-cell Engager, for the Treatment of GPC3+ Solid Tumors.

Paolo Meoni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.